RxDoctor Payments Data

Ashlie Burrow

Family · Cumming, GANPI 1326633942

Payments from drug & device makers

$1,098in general payments, 2019–2025

Across 44 payments — averaging $24.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$290
  • Lilly USA, LLC$174
  • Novo Nordisk$132
  • GSK$125
  • Inspire Medical Systems, Inc.$84
  • Alkermes, Inc.$73
  • plus $221 from 9 others

What the payments were for

  • Food & beverage$1,098100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,098 in reported general payments places this provider in the 65th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$13,590
Medicare patients
58
Services billed
197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide24$29,617
OzempicSemaglutide16$15,671
FarxigaDapagliflozin Propanediol22$15,100
EliquisApixaban25$14,058
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,779
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,536
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,109
Albuterol Sulfate HfaAlbuterol Sulfate37$835
Omeprazole45$773
Rosuvastatin Calcium23$665
Atorvastatin Calcium67$603
Levothyroxine Sodium61$563
Gabapentin41$522
Lisinopril76$478
Duloxetine Hcl14$405

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$174$29,61724 claims
AstraZenecaFarxiga, Breztri Aerosphere$32$21,87933 claims
Novo NordiskOzempic$132$15,67116 claims
GSKAnoro Ellipta$125$6,53614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,258 family providers in Georgia.

Other family in Cumming

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →